Table 1.

Recommendations from the European LeukemiaNet for the Management of CML

Recommendations from the European LeukemiaNet for the Management of CML4
Recommendations from the European LeukemiaNet for the Management of CML4

MMR indicates BCR/ABL1 <0.1%; CCA/Ph+, clonal chromosomal abnormalities in Ph+ cells; and CCA/Ph−, clonal chromosomal abnormalities in Ph− cells.

* Loss of MMR should be confirmed in 2 consecutive quantitative RT-PCR tests, of which one has a BCR/ABL1 transcripts level >1%.

Monitoring is performed by metaphase cytogenetics on bone marrow aspirate sample and/or by quantitative RT-PCR for BCR/ABL1 transcript levels on blood samples.

Close Modal

or Create an Account

Close Modal
Close Modal